EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas

Jungang Chen, Zhengyu Wang, Tran Phuc, Zhigang Xu, Donglin Yang, Zhengzhu Chen, Zhen Lin, Samantha Kendrick, Lu Dai, Hong-Yu Li, Zhiqiang Qin iD

PLOS Pathogens · 13.01.2023 · 19 (1) · e1011089

DOI: 10.1371/journal.ppat.1011089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 13.01.2023. Verfasst von Jungang Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States …. Hauptthemen laut MEDLINE: Lymphoma, Primary Effusion, Herpesvirus 8, Human, Sarcoma, Kaposi. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Arkansas Bioscience Institute, Winthrop P. Rockefeller Cancer Institute Team Science Award and VCRI Pioneer Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary effusion lymphoma (PEL) caused by Kaposi sarcoma–associated herpesvirus (KSHV) is an aggressive malignancy with poor prognosis even under chemotherapy. Currently, there is no specific treatment for PEL therefore requiring new therapies. Both histone deacetylases (HDACs) and bromodomain-containing protein 4 (BRD4) have been found as therapeutic targets for PEL through inducing viral lytic reactivation. However, the strategy of dual targeting with one agent and potential synergistic effects have never been explored. In the current study, we first demonstrated the synergistic effect of concurrently targeting HDACs and BRD4 on KSHV reactivation by using SAHA or entinostat (HDACs inhibitors) and (+)-JQ1 (BRD4 inhibitor), which indicated dual blockage of HDACs/BRD4 is a viable therapeutic approach. We were then able to rationally design and synthesize a series of new small-molecule inhibitors targeting HDACs and BRD4 with a balanced activity profile by generating a hybrid of the key binding motifs between (+)-JQ1 and entinostat or SAHA. Upon two iterative screenings of optimized compounds, a pair of epimers, 009P1 and 009P2, were identified to better inhibit the growth of KSHV positive lymphomas compared to (+)-JQ1 or SAHA alone at low nanomolar concentrations, but not KSHV negative control cells or normal cells. Mechanistic studies of 009P1 and 009P2 demonstrated significantly enhanced viral reactivation, cell cycle arrest and apoptosis in KSHV+ lymphomas through dually targeting HDACs and BRD4 signaling activities. Importantly, in vivo preclinical studies showed that 009P1 and 009P2 dramatically suppressed KSHV+ lymphoma progression with oral bioavailability and minimal visible toxicity. These data together provide a novel strategy for the development of agents for inducing lytic activation-based therapies against these viruses-associated malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Primary EffusionHerpesvirus 8, HumanSarcoma, KaposiHumansTranscription FactorsNuclear ProteinsHistone Deacetylase InhibitorsCell Line, TumorCell Cycle ProteinsBenzamidesPyridinesBromodomain Containing Proteins

Substanzen

Transcription FactorsNuclear ProteinsHistone Deacetylase InhibitorsCell Cycle ProteinsentinostatBenzamidesPyridinesBRD4 protein, humanBromodomain Containing Proteins

Autor:innen und Institutionen

  • Department of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
  • College of Pharmacy, Chongqing University of Arts and Sciences, Yongchuan, Chongqing, China.
  • Department of Pathology, Tulane University Health Sciences Center, Tulane Cancer Center, New Orleans, Louisiana, United States of America.
  • Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.

ORCID-Profile: Zhiqiang Qin

Förderung

  • NIGMS NIH HHS
  • Arkansas Bioscience Institute
  • Winthrop P. Rockefeller Cancer Institute Team Science Award and VCRI Pioneer Award
  • NIH COBRE
  • U.S.-Japan Cooperative Medical Sciences Program Collaborative Award
  • Tulane school of medicine faculty research pilot grant
  • Carol Lavin Bernick faculty grant
  • ARA endowment

Zitieren

APA

Chen, J., Wang, Z., Phuc, T., Xu, Z., Yang, D., Chen, Z., Lin, Z., Kendrick, S., Dai, L., Li, H. Y., & Qin, Z. (2023). Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas. PLOS Pathogens, 19(1), e1011089. https://doi.org/10.1371/journal.ppat.1011089

Vancouver

Chen J, Wang Z, Phuc T, Xu Z, Yang D, Chen Z, et al. Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas. PLOS Pathogens. 2023;19(1):e1011089. doi:10.1371/journal.ppat.1011089

BibTeX
@article{Chen2023,
  author = {Chen, Jungang and Wang, Zhengyu and Phuc, Tran and Xu, Zhigang and Yang, Donglin and Chen, Zhengzhu and Lin, Zhen and Kendrick, Samantha and Dai, Lu and Li, Hong-Yu and Qin, Zhiqiang},
  title = {Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas},
  journal = {PLOS Pathogens},
  year = {2023},
  volume = {19},
  number = {1},
  pages = {e1011089},
  doi = {10.1371/journal.ppat.1011089}
}
Kostenlos starten →